Skip to main content
Smrithi Ravikumar on Muck Rack

Smrithi Ravikumar

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Smrithi

Contact Smrithi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety

|
By Atharva Karulkar, Hasmukh Jain, Neeraj Sidharthan, Dinesh Bhurani, Sameer Melinkeri, Pavan Kumar Boyella, Prashant Mehta, Esha Kaul, Sanket R. Shah, Chandran Nair, Rahul Bhargava, Bhausaheb Bagal, Lingaraj Nayak, Alok Shetty, Hari Menon, Devanshi Kalra, Shalini Purwar, Nirali Shah, Terry Fry, Nitin Jain, Sattva Neelapu, Manju Sengar, Rahul Purwar, Jayachandran P. K, Rakesh Reddy Boya, Ram Abhinav, Smrithi Ravikumar, Jayashree Thorat
| Nature Verified
Abstract Talicabtagene autoleucel (tali-cel) is the first humanized CD19-directed CAR-T cell therapy approved in India for relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). Here, we integrated clinical and manufacturing operations through a centralized coordination unit (CCU) and evaluated tali-cel implementation.
Open in Who Shared Issue with article?
See all 1 articles